GLP-1 receptor agonists have transformed diabetes care, but the long-term safety of GLP-1 therapies has become an important topic as treatment continues for many years. Initially, clinicians prescribed these medications primarily for glycemic control in patients with type 2 diabetes. However, their role has expanded due to additional benefits in …

Chronic kidney disease (CKD) remains one of the most serious complications associated with diabetes, affecting millions of patients worldwide. While SGLT2 inhibitors have become foundational therapies for protecting kidney function, researchers are increasingly examining whether other drug classes may also slow renal decline. In particular, growing interest surrounds how GLP-1 …

Weight loss conversations often focus on a simple question: how much lean mass is preserved? However, emerging research suggests that the story is more complex. GLP-1 receptor agonists are well known for promoting weight loss and improving glycemic control, but scientists are increasingly examining how these medications influence muscle health …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes and obesity. However, one question clinicians increasingly ask is whether gastric motility adapts during long-term GLP-1 therapy. These medications slow gastric emptying, which contributes to appetite control and postprandial glucose reduction. Yet the human body often …

GLP-1 receptor agonists have transformed diabetes and obesity treatment, yet safety questions still surface in clinic visits. One concern continues to appear in patient discussions: thyroid cancer risk. The topic often traces back to early rodent studies that triggered boxed warnings for medullary thyroid carcinoma (MTC). However, clinicians today rely …

GLP-1 receptor agonists and dual incretin therapies are transforming diabetes care. These medications often produce significant and rapid improvements in glycemic control, sometimes lowering A1C levels faster than traditional treatments. However, clinicians have begun asking an important question: could rapid A1C reduction with GLP-1 therapy increase retinopathy risk in some …

Managing the risk of hypoglycemia remains a central challenge in diabetes care, even as newer therapies lower the rate of severe events. Although GLP-1 receptor agonists and SGLT2 inhibitors have reshaped treatment strategies, insulin and sulfonylureas are still widely used, especially among older adults and patients with chronic kidney disease …

Continuous glucose monitoring has transformed diabetes care, but are we fully using the data it provides? In 2026, time in range is moving beyond a simple CGM metric and becoming a formal therapeutic target in diabetes care. While A1C remains important, time in range (TIR) offers a more dynamic and …

When managing type 2 diabetes, should clinicians still begin with one medication and wait for treatment failure before intensifying therapy? Increasingly, evidence suggests that early combination therapy in type 2 diabetes may provide better durability, faster glycemic control, and improved cardiovascular and kidney outcomes in high-risk patients. While metformin monotherapy …

GLP-1 receptor agonists have transformed type 2 diabetes and obesity management, but the cost-effectiveness of GLP-1 therapies is now at the center of payer and policy debates. With drugs like semaglutide, liraglutide, dulaglutide, and tirzepatide expanding beyond glycemic control into cardiovascular and weight management, a key question remains: do their …